Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Summer;18(3):377-83.
doi: 10.1176/jnp.2006.18.3.377.

Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study

Daniel Weintraub  1 , Donna Taraborelli, Knashawn H Morales, John E Duda, Ira R Katz, Matthew B Stern
Affiliations
Clinical Trial

Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study

Daniel Weintraub et al. J Neuropsychiatry Clin Neurosci. 2006 Summer.

Abstract

Depression and antidepressant use are common in Parkinson's disease, but the benefit of selective serotonin reuptake inhibitor (SSRI) treatment in this population has not been established. The authors treated 14 Parkinson's disease patients with major depression with escitalopram in an open-label study. Although treatment was well tolerated and correlated with a significant decrease in Inventory of Depressive Symptomatology score, response and remission rates were only 21% and 14%, respectively. However, half of the subjects met Clinical Global Impression-Improvement criteria for response. In Parkinson's disease, either SSRIs may have limited antidepressant effects, or the use of existing depression diagnostic and rating instruments may be problematic.

PubMed Disclaimer

Figures

FIGURE 1a
FIGURE 1a
Change in Inventory of Depressive Symptomatology (IDS) Score
See this image and copyright information in PMC

References

    1. Weintraub D. Diagnosing and treating depression in patients with Parkinson’s disease. Psychiatr Ann. 2004;34:299–304.
    1. Richard IH, Kurlan R Parkinson Study Group. A survey of anti-depressant use in Parkinson’s disease. Neurology. 1997;49:1168–1170. - PubMed
    1. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson’s disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry. 1998;52:163–169.
    1. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003;18:552–554. - PubMed
    1. Dell’Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24:221–227. - PubMed

Publication types

MeSH terms

Substances